Literature DB >> 21273671

Lactoferrin inhibits the growth of nasal polyp fibroblasts.

Beata Nadolska1, Marcin Frączek, Tomasz Kręcicki, Maja Kocięba, Michał Zimecki.   

Abstract

The aim of this study was to evaluate the effects of lactoferrin (LF) on the growth of fibroblasts derived from nasal polyps. We showed that the proliferation of fibroblasts was inhibited in a dose-dependent manner by both native and recombinant LF. The greatest inhibition of proliferation was caused by human milk-derived, iron-saturated LF. The inhibition of fibroblast proliferation was not species specific because bovine LF also was active. The interaction between LFs and a putative cell receptor did not depend on the sugar composition of the glycan moiety of the LF molecule because lactoferrins of different origins were active and the addition of monosaccharides to the cultures did not block proliferation. However, the treatment of fibroblasts with sodium chlorate (an inhibitor of glycosaminoglycan sulfation) or the addition of heparin abolished the inhibitory effect of LF, suggesting that LF binds heparan sulfate-containing proteoglycans. The significance of LF in nasal excretions in controlling polyp formation is discussed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21273671     DOI: 10.1016/s1734-1140(10)70376-5

Source DB:  PubMed          Journal:  Pharmacol Rep        ISSN: 1734-1140            Impact factor:   3.024


  6 in total

1.  Risk of nasopharyngeal carcinoma associated with polymorphic lactotransferrin haplotypes.

Authors:  Yanhong Zhou; Wei Wang; Danwei Zheng; Shuping Peng; Wei Xiong; Jian Ma; Zhaoyang Zeng; Minghua Wu; Ming Zhou; Juanjuan Xiang; Bo Xiang; Xiaoling Li; Xiayu Li; Guiyuan Li
Journal:  Med Oncol       Date:  2011-10-20       Impact factor: 3.064

2.  Different activations of toll-like receptors and antimicrobial peptides in chronic rhinosinusitis with or without nasal polyposis.

Authors:  Andor Hirschberg; Maria Kiss; Edit Kadocsa; Hilda Polyanka; Kornelia Szabo; Zsolt Razga; Zsolt Bella; Laszlo Tiszlavicz; Lajos Kemeny
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-10-30       Impact factor: 2.503

3.  Lactoferrin regulates an axis involving CD11b and CD49d integrins and the chemokines MIP-1α and MCP-1 in GM-CSF-treated human primary eosinophils.

Authors:  Colleen S Curran; Paul J Bertics
Journal:  J Interferon Cytokine Res       Date:  2012-06-25       Impact factor: 2.607

4.  Association of the -33C/G OSF-2 and the 140A/G LF gene polymorphisms with the risk of chronic rhinosinusitis with nasal polyps in a Polish population.

Authors:  Hanna Zielinska-Blizniewska; Przemyslaw Sitarek; Jaroslaw Milonski; Lukasz Dziki; Karolina Przybylowska; Jurek Olszewski; Ireneusz Majsterek
Journal:  Mol Biol Rep       Date:  2011-12-16       Impact factor: 2.316

5.  Expression levels of JNK associated with polymorphic lactotransferrin haplotypes in human nasopharyngeal carcinoma.

Authors:  Gengqiu Luo; Yanhong Zhou; Wei Yi; Hong Yi
Journal:  Oncol Lett       Date:  2016-06-15       Impact factor: 2.967

6.  Antidiabetic efficacy of lactoferrin in type 2 diabetic pediatrics; controlling impact on PPAR-γ, SIRT-1, and TLR4 downstream signaling pathway.

Authors:  Waleed A Mohamed; Mona F Schaalan
Journal:  Diabetol Metab Syndr       Date:  2018-12-04       Impact factor: 3.320

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.